NEW YORK, July 24, 2017 /PRNewswire/ -- WebMD Health
Corp. (NASDAQ: WBMD), the leading source of health information,
today announced preliminary financial results for the three months
ended June 30, 2017.
Preliminary Results for the Three Months Ended June 30, 2017
WebMD expects that its second quarter revenue, net income and
Adjusted EBITDA will be above previously stated financial guidance
for the second quarter.
- Revenue for the second quarter is expected to be approximately
$176 million, an increase of
approximately 5% from the prior year period. Prior financial
guidance for the quarter was $170 million to
$173 million.
- Net income for the second quarter is expected to be
approximately $18.9 million, an
increase of approximately 6% from the prior year period. Prior
financial guidance for the quarter was $16.9
million to $18.5 million. Net income for the second quarter
includes an after-tax expense of $1.3
million, related to third-party costs incurred in connection
with the review of strategic alternatives and an after-tax gain of
approximately $0.3 million related to
the sale of property.
- Adjusted EBITDA for the second quarter is expected to be
approximately $54 million, an
increase of approximately 8% from the prior year period. Prior
financial guidance for the quarter was $49
million to $51 million.
This information is preliminary and subject to the completion of
WebMD's normal closing process and finalization of quarterly
financial and accounting procedures. WebMD is not planning to
hold a conference call regarding second quarter results.
About WebMD
WebMD Health Corp. (NASDAQ: WBMD) is the leading provider of
health information services, serving consumers, physicians,
healthcare professionals, employers, and health plans through our
public and private online portals, mobile platforms and
health-focused publications.
The WebMD Health Network includes WebMD.com, Medscape.com,
MedicineNet.com, eMedicineHealth.com, RxList.com, OnHealth.com,
Medscape Education (Medscape.org) and other WebMD owned sites and
apps.
*****************************
All statements contained in this press release, other than
statements of historical fact, are forward-looking statements,
including those regarding preliminary second quarter results (which
reflect what WebMD currently expects to report and are subject to
adjustment). These statements speak only as of the date of this
press release, are based on our current plans and expectations, and
involve risks and uncertainties that could cause actual future
events or results to be different than those described in or
implied by such forward-looking statements. Except as required by
applicable law or regulation, we do not undertake any obligation to
update our forward-looking statements to reflect future events or
circumstances.
*************************************
This press release, and the accompanying table, include both
financial measures in accordance with accounting principles
generally accepted in the United States
of America, or GAAP, as well as certain non-GAAP financial
measures. A reconciliation of net income (a GAAP financial
measure) to Adjusted EBITDA (a non-GAAP financial measure) and an
"Explanation of Non-GAAP Financial Measures" are attached to this
press release.
*****************************
WebMD®, Medscape®, CME Circle®, Medpulse®, eMedicine®,
MedicineNet®, theheart.org® and RxList® are among the trademarks of
WebMD Health Corp. or its subsidiaries.
WEBMD HEALTH
CORP.
|
PRELIMINARY FINANCIAL
INFORMATION
|
(in millions,
except per share amounts)
|
(unaudited)
|
|
|
|
|
Quarter
Ended
|
|
|
|
|
June 30,
2017
|
|
|
|
|
(Preliminary)
|
|
|
|
|
|
Revenue
|
|
$
176.0
|
|
|
|
|
|
Net income
|
|
$
18.9
|
|
|
|
|
|
Interest, taxes,
non-cash and other items (a)
|
|
|
|
Interest
income
|
|
(1.9)
|
|
Interest
expense
|
|
7.0
|
|
Income tax
provision
|
|
11.9
|
|
Depreciation and
amortization
|
|
7.6
|
|
Non-cash stock-based
compensation
|
|
8.9
|
|
Transaction
expense
|
|
2.1
|
|
Other
income
|
|
(0.6)
|
|
|
|
|
|
Earnings before
interest, taxes, non-cash
|
|
|
|
and other items
("Adjusted EBITDA") (b)
|
|
$
53.9
|
|
|
|
|
|
|
|
|
|
|
Net income per common
share:
|
|
|
|
|
Basic
|
|
$
0.51
|
|
|
Diluted
|
|
$
0.43
|
|
|
|
|
|
Weighted-average
shares outstanding used in computing
|
|
|
|
income per common
share:
|
|
|
|
|
Basic
|
|
37.1
|
|
|
Diluted
|
|
54.4
|
|
|
|
|
|
|
|
|
|
|
(a)
|
Reconciliation of net
income to Adjusted EBITDA.
|
|
|
(b)
|
See Annex
A-Explanation of Non-GAAP Financial Measures.
|
|
|
|
|
|
|
|
Additional
information regarding preliminary results for the quarter ended
June 30, 2017:
|
|
-
|
Transaction expense
represents professional fees incurred in connection with
the
|
|
|
process conducted by
the Board of Directors to explore strategic alternatives
|
|
|
for the
Company.
|
|
|
|
-
|
Other income
represents a gain on the sale of property.
|
|
|
ANNEX A
Explanation of Non-GAAP Financial
Measures
The accompanying WebMD Health Corp. press release and attachment
include both financial measures in accordance with U.S. generally
accepted accounting principles, or GAAP, as well as non-GAAP
financial measures. The non-GAAP financial measures represent
earnings before interest, taxes, non-cash and other items (which we
refer to as "Adjusted EBITDA"). Adjusted EBITDA should be
viewed as supplemental to, and not as an alternative for net income
or loss calculated in accordance with GAAP (referred to below as
"net income"). The attachment to the press release includes a
reconciliation of net income to Adjusted EBITDA.
Adjusted EBITDA is used by our management as an additional
measure of our company's performance for purposes of business
decision-making, including developing budgets, managing
expenditures, and evaluating potential acquisitions or
divestitures. Period-to-period comparisons of Adjusted EBITDA
help our management identify additional trends in our company's
financial results that may not be shown solely by period-to-period
comparisons of net income. In addition, we may use Adjusted
EBITDA in the incentive compensation programs applicable to some of
our employees in order to evaluate our company's performance.
Our management recognizes that Adjusted EBITDA has inherent
limitations because of the excluded items, particularly those items
that are recurring in nature. In order to compensate for
those limitations, management also reviews the specific items that
are excluded from Adjusted EBITDA, but included in net income, as
well as trends in those items. The amounts of those items are
set forth, for the applicable periods, in the reconciliations of
Adjusted EBITDA to net income that accompany our press releases and
disclosure documents containing non-GAAP financial measures,
including the reconciliation contained in the accompanying press
release attachment.
We believe that the presentation of Adjusted EBITDA is useful to
investors in their analysis of our results for reasons similar to
the reasons why our management finds it useful and because it helps
facilitate investor understanding of decisions made by management
in light of the performance metrics used in making those
decisions. In addition, as more fully described below, we
believe that providing Adjusted EBITDA, together with a
reconciliation of Adjusted EBITDA to net income, helps investors
make comparisons between our company and other companies that may
have different capital structures, different effective income tax
rates and tax attributes, different capitalized asset values and/or
different forms of employee compensation. However, Adjusted
EBITDA is intended to provide a supplemental way of comparing our
company with other public companies and is not intended as a
substitute for comparisons based on net income. In making any
comparisons to other companies, investors need to be aware that
companies use different non-GAAP measures to evaluate their
financial performance. Investors should pay close attention
to the specific definition being used and to the reconciliation
between such measures and the corresponding GAAP measures provided
by each company under applicable SEC rules.
The following is an explanation of the items excluded by us from
Adjusted EBITDA but included in net income:
- Depreciation and Amortization. Depreciation
and amortization expense is a non-cash expense relating to capital
expenditures and intangible assets arising from acquisitions that
are expensed on a straight-line basis over the estimated useful
life of the related assets. We exclude depreciation and
amortization expense from Adjusted EBITDA because we believe that
(i) the amount of such expenses in any specific period may not
directly correlate to the underlying performance of our business
operations and (ii) such expenses can vary significantly between
periods as a result of new acquisitions and full amortization of
previously acquired tangible and intangible assets.
Accordingly, we believe that this exclusion assists management and
investors in making period-to-period comparisons of operating
performance. Investors should note that the use of tangible
and intangible assets contributed to revenue in the periods
presented and will contribute to future revenue generation and
should also note that such expense will recur in future
periods.
- Stock-Based Compensation Expense.
Stock-based compensation expense is a non-cash expense arising from
the grant of stock-based awards to employees. We believe that
excluding the effect of stock-based compensation from Adjusted
EBITDA assists management and investors in making period-to-period
comparisons in our company's operating performance because
(i) the amount of such expenses in any specific period may not
directly correlate to the underlying performance of our business
operations and (ii) such expenses can vary significantly
between periods as a result of the timing of grants of new
stock-based awards, including grants in connection with
acquisitions. Additionally, we believe that excluding
stock-based compensation from Adjusted EBITDA assists management
and investors in making meaningful comparisons between our
company's operating performance and the operating performance of
other companies that may use different forms of employee
compensation or different valuation methodologies for their
stock-based compensation. Investors should note that
stock-based compensation is a key incentive offered to employees
whose efforts contributed to the operating results in the periods
presented and are expected to contribute to operating results in
future periods. Investors should also note that such expenses
will recur in the future.
- Interest Income and Expense. Interest
income is associated with the level of marketable debt securities
and other interest bearing accounts in which we invest, and
interest expense is related to our company's capital structure
(including non-cash interest expense relating to our convertible
notes). Interest income and expense varies over time due to a
variety of financing transactions and due to acquisitions and
divestitures that we have entered into or may enter into in the
future. We have, in the past, issued convertible debentures,
repurchased shares in cash tender offers and repurchased shares and
convertible debentures through other repurchase transactions, and
completed the divestiture of certain businesses. We exclude
interest income and interest expense from Adjusted EBITDA (i)
because these items are not directly attributable to the
performance of our business operations and, accordingly, their
exclusion assists management and investors in making
period-to-period comparisons of operating performance and (ii) to
assist management and investors in making comparisons to companies
with different capital structures. Investors should note that
interest income and expense will recur in future
periods.
- Income Tax Provision (Benefit). We maintain
a valuation allowance on a portion of our net deferred tax assets
(including our net operating loss carryforwards), the amount of
which may change from quarter to quarter based on factors that are
not directly related to our results for the quarter. The
valuation allowance is either adjusted through the statement of
operations or additional paid-in capital. The timing of such
adjustments has not been consistent and as a result, our income tax
expense can fluctuate significantly from period to period in a
manner not directly related to our operating performance. We
exclude the income tax provision (benefit) from Adjusted EBITDA (i)
because we believe that the income tax provision (benefit) is not
directly attributable to the underlying performance of our business
operations and, accordingly, its exclusion assists management and
investors in making period-to-period comparisons of operating
performance and (ii) to assist management and investors in
making comparisons to companies with different tax
attributes. Investors should note that income tax provision
(benefit) will recur in future periods.
- Other Items. We engage in other activities
and transactions that can impact our net income. In recent
periods, these other items included, but were not limited to:
(i) gain on investments; (ii) settlements of litigation or claims;
(iii) loss on repurchases of our convertible notes; (iv) severance
expense; (v) gain on sale of property; and (vi) legal fees and
other expenses incurred in connection with the process conducted by
our Board of Directors to explore strategic alternatives for our
company. We exclude these other items from Adjusted EBITDA
because we believe these activities or transactions are not
directly attributable to the performance of our business operations
and, accordingly, their exclusion assists management and investors
in making period-to-period comparisons of operating
performance. Investors should note that some of these other
items may recur in future periods.
View original
content:http://www.prnewswire.com/news-releases/webmd-provides-preliminary-second-quarter-financial-results-300492705.html
SOURCE WebMD Health Corp.